X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (396) 396
Newspaper Article (44) 44
Conference Proceeding (13) 13
Book / eBook (11) 11
Book Review (9) 9
Web Resource (7) 7
Book Chapter (6) 6
Patent (6) 6
Dissertation (4) 4
Magazine Article (3) 3
Report (2) 2
Publication (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (154) 154
female (87) 87
hematology (74) 74
male (74) 74
aged (60) 60
middle aged (59) 59
peripheral vascular disease (56) 56
venous thromboembolism (55) 55
rivaroxaban (46) 46
adult (43) 43
anticoagulants (41) 41
risk factors (41) 41
anticoagulants - therapeutic use (40) 40
prevention (37) 37
thromboembolism (37) 37
deep-vein thrombosis (34) 34
atrial fibrillation (32) 32
anticoagulants - administration & dosage (29) 29
thrombosis (28) 28
anticoagulants - adverse effects (26) 26
treatment outcome (26) 26
aged, 80 and over (25) 25
prospective studies (24) 24
stroke (24) 24
venous thromboembolism - prevention & control (24) 24
animals (23) 23
hemorrhage - chemically induced (21) 21
risk assessment (21) 21
analysis (20) 20
enoxaparin (20) 20
heparin - therapeutic use (20) 20
molecular-weight heparin (20) 20
internal medicine (19) 19
venous thrombosis - prevention & control (19) 19
administration, oral (18) 18
heparin (18) 18
cardiac & cardiovascular systems (17) 17
drug therapy (17) 17
prophylaxis (17) 17
care and treatment (16) 16
double-blind method (16) 16
factor xa inhibitors (16) 16
heparin - adverse effects (16) 16
heparin, low-molecular-weight - therapeutic use (16) 16
pulmonary-embolism (16) 16
registries (16) 16
research (16) 16
risk (16) 16
thromboprophylaxis (16) 16
anticoagulation (15) 15
health risk assessment (15) 15
management (15) 15
mice (15) 15
patients (15) 15
safety (15) 15
thromboembolism - prevention & control (15) 15
atrial fibrillation - drug therapy (14) 14
medicine & public health (14) 14
mortality (14) 14
postoperative complications - prevention & control (14) 14
surgery (14) 14
unfractionated heparin (14) 14
warfarin (14) 14
bleeding (13) 13
medicine, general & internal (13) 13
practice guidelines as topic (13) 13
stroke - prevention & control (13) 13
time factors (13) 13
abridged index medicus (12) 12
adolescent (12) 12
bay-59-7939 (12) 12
medicine (12) 12
morpholines - therapeutic use (12) 12
oncology (12) 12
pharmacology & pharmacy (12) 12
pulmonary embolism (12) 12
pulmonary embolism - prevention & control (12) 12
thiophenes - therapeutic use (12) 12
venous thrombosis (12) 12
venous thrombosis - drug therapy (12) 12
atrial fibrillation - complications (11) 11
dabigatran (11) 11
immunology (11) 11
morpholines - administration & dosage (11) 11
thiophenes - administration & dosage (11) 11
blood coagulation - drug effects (10) 10
cardiology (10) 10
case-control studies (10) 10
expression (10) 10
incidence (10) 10
prevalence (10) 10
risk-factors (10) 10
studies (10) 10
thromboembolism - drug therapy (10) 10
total hip-replacement (10) 10
antithrombotic therapy (9) 9
cardiac arrhythmia (9) 9
chemistry (9) 9
clinical medicine (9) 9
clinical trials (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Applied Thrombosis/Hemostasis, ISSN 1076-0296, 10/2006, Volume 12, Issue 4, pp. 445 - 450
Journal Article
Clinical and applied thrombosis/hemostasis, ISSN 1938-2723, 2012, Volume 18, Issue 2, pp. 159 - 165
In 2 double-blind studies, ambulatory patients with objectively proven, disseminated metastatic breast carcinoma (TOPIC-1) or stage III/IV non–small-cell lung... 
anticoagulants | thrombosis prophylaxis | deep venous thrombosis | venous thromboembolism | low-molecular-weight heparins | SURVIVAL | SURGERY | THROMBOSIS | RANDOMIZED-TRIAL | CHEMOTHERAPY | PROPHYLAXIS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Lung Neoplasms - drug therapy | Pulmonary Embolism - prevention & control | Humans | Middle Aged | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Lung Neoplasms - pathology | Male | Heparin, Low-Molecular-Weight - therapeutic use | Thrombophilia - etiology | Warfarin - therapeutic use | Early Termination of Clinical Trials | Venous Thromboembolism - prevention & control | Carcinoma - complications | Female | Thrombophilia - drug therapy | Carcinoma - secondary | Carcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Double-Blind Method | Treatment Outcome | Thrombocytopenia - chemically induced | Breast Neoplasms - drug therapy | Lung Neoplasms - complications | Venous Thromboembolism - etiology | Breast Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - complications | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pulmonary Embolism - etiology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Hemorrhage - chemically induced | Neoplasm Staging | Breast cancer | Metastasis | Thromboembolism | Health risk assessment
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
by Haas, S
HAMOSTASEOLOGIE, ISSN 0720-9355, 02/2019, Volume 39, Issue 1, pp. 62 - 66
Low molecular weight heparins and fondaparinux have been the cornerstones for prevention of venous thromboembolism (VTE) in acutely ill medical patients for... 
ENOXAPARIN | PROPHYLAXIS | PLACEBO | ACUTELY ILL | nonvitamin K antagonist oral anticoagulants | medical patients | low molecular weight heparins | THROMBOPROPHYLAXIS | HEMATOLOGY | VTE prevention | UNFRACTIONATED HEPARIN
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 23, pp. 2167 - 2177
In this clinical trial of hospitalized medically ill patients, extended thromboprophylaxis (30 days) with apixaban had similar efficacy to that of a shorter... 
REPLACEMENT | MEDICINE, GENERAL & INTERNAL | VENOUS THROMBOEMBOLISM | PULMONARY-EMBOLISM | DOUBLE-BLIND | PREVENTION | PLACEBO-CONTROLLED TRIAL | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thromboembolism - epidemiology | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Drug Administration Schedule | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Heart Failure - drug therapy | Pulmonary Embolism - mortality | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Respiratory Insufficiency - drug therapy | Drugs | Enoxaparin | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Thrombolytic drugs | Comparative analysis | Drug therapy | Heart failure | Fees & charges | Anticoagulants | Compression | Prophylaxis | Congestive heart failure | Thrombosis | Bleeding | Embolism | Compression therapy | Ultrasonic imaging | Hospitals | Safety | Thromboembolism | Health risk assessment | Ultrasound | Respiratory Insufficiency | Hemorrhage | Life Sciences | Venous Thromboembolism | Heart Failure | Pyrazoles | Pyridones | Human health and pathology | Pulmonary Embolism
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 06/2015, Volume 140, Issue S 01, pp. S13 - S14
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
... Enoxaparin for Thromboprophylaxis after Hip Arthroplasty Bengt I. Eriksson, M.D., Ph.D., Lars C. Borris, M.D., Richard J. Friedman, M.D., Sylvia Haas, M.D., Menno V... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Cell reports (Cambridge), ISSN 2211-1247, 2017, Volume 20, Issue 10, pp. 2513 - 2524
Research in neuroscience increasingly relies on the mouse, a mammalian species that affords unparalleled genetic tractability and brain atlases. Here, we... 
DECISION | ACTIVATION | AREA | DISCRIMINATION | ORIENTATION | NEURONS | CONTRAST | PARIETAL CORTEX | TRANSGENIC MICE | CELL BIOLOGY | Psychophysics - methods | Animals | Dopaminergic Neurons - metabolism | Choice Behavior - physiology | Female | Male | Mice | Visual Cortex - metabolism | Photic Stimulation | Visual Cortex - physiology
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
Journal Article